Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat

Stock Track

Feb 06, 2025

Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.

For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.

While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191708832"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191708832\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191708832?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-06 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191708832","market":"hk","top_or_hot":-1,"title":"Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat","media":"Stock Track","content":"<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Omnicell Plunges 5.39% in Pre-Market as Q4 Earnings Disappoint Despite Revenue Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-06 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.</p>\n\n<p>For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.</p>\n\n<p>While Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"","article_id":"1191708832","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191708832","pubTimestamp":1738849486,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Omnicell Inc.  shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.For the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.While Omnicell delivered strong revenue growth of 19% y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell"},"translate_title":"尽管营收超出预期，但第四季度盈利令人失望，Omnicell盘前暴跌5.39%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":1},"content_text":"Omnicell Inc. (OMCL) shares plummeted 5.39% in pre-market trading on Thursday, following the company's mixed fourth quarter 2024 results reported after the market close on Wednesday.\nFor the quarter ended December 31, 2024, the medication management solutions provider posted earnings of $0.34 per share, missing the consensus estimate of $0.57 per share. However, revenue came in at $306.9 million, surpassing analysts' expectations of $296.9 million.\nWhile Omnicell delivered strong revenue growth of 19% year-over-year, driven by improved macroeconomic conditions and timing of XT Series system implementations, higher costs weighed on profitability. The company cited increased expenses related to investments in generative AI, autonomous driving technologies, and other growth initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}